Introduction {#s1}
============

While the recently improved treatment strategies have resulted in better survival statistics in many cancers, in non-small cell lung cancer (NSCLC) the 1-year overall survival at a locally advanced or metastatic stage barely exceeds 20%.[@R1] Although key mutations aid clinical decision-making and facilitate the application of targeted therapies, radical improvements have not been observed and the 5-year survival rate remains at approximately 5%.[@R1] Although next-generation sequencing has become a cornerstone of therapy guidance,[@R2] clinical decision-making remains difficult due to the histological diversity of NSCLC (adeno, squamosous, large cell) and the variation of the mutation characteristics of the different subtypes.[@R3] Based on clinical guidelines, patients with advanced lung adenocarcinoma (AC) are tested for the presence of Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) and epidermal growth factor receptor (EGFR) mutations and rearrangements involving anaplastic lymphoma kinase (ALK).[@R4] Unfortunately, analysis of tumour mutations can only describe the mutations existing at the specific location where the sample was taken from and at the time of sample taking. By the time therapy is selected, additional mutations may have occurred.[@R5] Due to the diversity of histology as well as mutations in NSCLC, the first-line treatment of locally advanced or inoperable cancer is platinum based, which can in itself dramatically increase the mutation rate.[@R7] The relatively slow acting immunotherapies are only considered as an alternative in specific cases[@R8]; therefore, chemotherapy remains the principal treatment modality in advanced NSCLC. To improve chemotherapy response rates, drug sensitivity assays have been under intense investigation.[@R9] It was recognised that tissues derived from the original tumour represent the tumour composition suitably well to test chemosensitivity on freshly isolated tumour cells in vitro.[@R10] Most published tests, however, have not been performed on advanced NSCLC.[@R9] While the statistical analysis of data in the current literature involving different tumours looks convincing, clinicians remain wary of such tests due to the clinical complexity of individual treatment responses. In the present study, we have performed in vitro drug sensitivity analysis in advanced NSCLC AC samples, to investigate sensitivity to currently recommended drugs and compared the results to clinical therapy response.

Materials and methods {#s2}
=====================

Resected solid tissue samples were digested using a Miltenyi Tumor Dissociation Kit (Miltenyi Biotec, Auburn, USA). Cells from pleural fluid were centrifuged (600g, 10 min), then isolated by Ficol separation. Red blood cells were removed by Red Blood Cell Lysis Buffer (Roche, Mannheim, Germany). Cells were cryopreserved using Cryo-SFM (PromoCell, Heidelberg, Germany) and stored at −80°C until used.

Cryopreserved tumour cells were combined with normal human lung fibroblast cells (1:1) and then aggregated in a low-attachment 96-well plate (Corning, New York, USA).[@R10]

Tissue aggregates were treated with chemotherapeutic compounds (Selleckem, Munich, Germany) selected by the oncoteam.

Concentrations for in vitro treatments were based on the literature[@R11] and in vitro concentration tests performed in our laboratory. Drug concentrations were as follows: cisplatin (7 µM),[@R13] carboplatin (CBP; 100 µM),[@R14] vinorelbine (150 nM),[@R15] gemcitabine (30 µM),[@R16] paclitaxel (100 nM),[@R17] pemetrexed (10 µM),[@R16] erlotinib (100 nM)[@R18] and gefitinib (100 nM).[@R19] Treatments were carried out for 48 hours at 37°C in 5% CO~2~ atmosphere in four parallels.

In vitro viability assay was performed using the three-dimensional (3D) CellTiter Glo (Promega, Madison, USA) kit, measured in a PerkinElmer Plate Reader (PerkinElmer, Waltham, USA).

CT, MRI, chest X-ray and abdominal ultrasound methods were used for Response Evaluation Criteria In Solid Tumours (RECIST V.1.1) evaluations.[@R20] In the selected patient populations, only stable (SD) and progressive (PD) diseases were distinguished. The in vitro chemosensitivity results were compared with the patients' clinical responses to chemotherapy at 2--3 months and patients were monitored over 18 months. One-way analysis of variance was used for statistical analysis and p\<0.05 was considered as significant.

Results {#s3}
=======

The study design and patient exclusion criteria are summarised in [figures 1 and 2](#F1 F2){ref-type="fig"}, respectively. Patient information is summarised in [table 1](#T1){ref-type="table"}.

![Study design. All the samples were freshly cryopreserved as single cell suspensions, then thawed when the oncoteam made a decision for therapy. Both the resected tissue and the tumour-enriched pleural effusion stained positive for TTF1 and both sample types were routinely tested for Kirsten rat sarcoma 2 viral oncogene homolog, epidermal growth factor receptor and anaplastic lymphoma kinase mutations. Single cell suspensions were cryopreserved and stored at −80°C until used. Samples were thawed and placed into three-dimensional (3D) aggregate cultures, then treated with the corresponding chemotherapeutic agent(s) selected by the oncoteam. Patient therapy responses were monitored and compared with the in vitro assay results. PD, progressive disease; SD, stable disease; TFF1, Thyroid transcription factor 1.](bmjresp-2019-000505f01){#F1}

![Exclusion criteria. Out of the 120 patients only 14 met the inclusion criteria, 10 for solid tumours and 4 for pleural effusions. The exclusion criteria are named in the boxes along with the number of patients excluded from the study. RECIST, Response Evaluation Criteria In Solid Tumours.](bmjresp-2019-000505f02){#F2}

###### 

Clinical data (Part A contains data of patients donating solid tumours, while part B contains a list of samples obtained from pleural effusions)

  Sample number                                    Mutations   Diagnosis          T      N     M     Intervention                Date of sampling           Clinical therapy            In vitro     Type of treatment   Beginning of therapy   End of therapy      Treatment before/after sampling   RECIST              RECIST date         PD-L1
  ------------------------------------------------ ----------- ------------------ ------ ----- ----- --------------------------- -------------------------- --------------------------- ------------ ------------------- ---------------------- ------------------- --------------------------------- ------------------- ------------------- ------------------
  **A. Patient data of solid tumours**                                                                                                                                                                                                                                                                                                        
  Solid tumors                                                                                                                                                                                                                                                                                                                                
   1                                               KRAS        NSCLC-Adenocc.     pT1b   pN1   Mx    Complete tumour resection   27 October 2015            Observation                 --                               27 October 2015        22 May 2017         After                             PD                  29 March 2017       \>50% (Positive)
                                                               pT1b               N3     M1a                                     Cisplatin + pemetrexed     Tested                      Palliative   23 May 2017         09 August 2017         After               SD                                25 August 2017                          
                                                               T3                 N3     M1c                                     Pemetrexed mono            Tested                      Palliative   17 October 2017     28 November 2017       After               PD                                14 December 2017                        
   2                                               WT          NSCLC-Adenocc.     pT2a   N1    Mx    Complete tumour resection   01 December 2015           Cisplatin + vinorelbine     Tested       Adjuvant            06 January 2016        24 June 2016        After                             SD                  --                  Negative
   3                                               KRAS        NSCLC-Adenocc.     pT3    pN2   Mx    Complete tumour resection   28 April 2016              Observation                 --                               29 April 2016          29 June 2016        After                             PD                  26 May 2016         Negative
                                                               pT3                pN2    M1a                                     Cisplatin + pemetrexed     Tested                      Palliative   30 June 2016        30 June 2016           After               PD                                05 July 2016                            
   4                                               KRAS        NSCLC-Adenocc.     pT3    N0    M1b   Complete tumour resection   03 May 2016                Cisplatin + gemcitabine     Tested       Adjuvant            07 July 2016           08 August 2016      After                             SD                  06 September 2017   Negative
   5                                               KRAS        NSCLC-Adenocc.     pT3a   N1    Mx    Complete tumour resection   26 June 2016               Cisplatin + vinorelbine     Tested       Adjuvant            08 August 2016         30 September 2016   After                             SD                  27 April 2017       Negative
   6                                               KRAS        NSCLC-Adenocc.     pT2a   pN2   M1c   Complete tumour resection   12 September 2016          Carboplatin + gemcitabine   Tested       Adjuvant            12 October 2016        07 December 2016    After                             PD                  24 January 2017     \<1% (Negative)
   7                                               KRAS        NSCLC - Adeno cc   pT2    pN1   Mx    Complete tumour resection   05 December 2016           Cisplatin+pemetrexed        Tested       Adjuvant            21 February 2017       03 May 2017         After                             SD                  23 May 2017         
   8                                                           NSCLC - Adeno cc   pT2a   pNx   Mx    Complete tumour resection   05 January 2017            Carboplatin -- paclitaxel   Tested       Adjuvant            28 March 2017          15 June 2017        After                             SD                  20 July 2017        
   9                                               KRAS        NSCLC - Adeno cc   pT2    pN1   Mx    Complete tumour resection   14 December 2015           Cisplatin + vinorelbine     Tested       Adjuvant            18 February 2016       08 April 2016                                         SD                  08 July 2016        
   10                                              EGFR        NSCLC - Adeno cc   pT2a   pN2   Mx    Complete tumour resection   19 December 2016           Cisplatin + vinorelbine     Tested       Adjuvant            09 February 2017       02 March 2017       After                             SD                  20 March 2017       
                                                               pT2a               pN2    Mx                                      Erlotinib mono             Tested                      Palliative   18 October 2017     13 August 2018         After               PD                                13 August 2018                          
  **B. Patient data of pleural effusion donors**                                                                                                                                                                                                                                                                                              
  Pleural effusions                                                                                                                                                                                                                                                                                                                           
   1                                               EGFR        NSCLC - Adeno cc   T3     Nx    M1b   Thoracic aspiration         20 February 2017           Gefitinib                   Tested       Palliative          04 February 2015       14 June 2017        During                            PD                  14 June 2017        Negative
   2                                               KRAS        NSCLC - Adeno cc   T2a    N2    M1a   Thoracic aspiration         06 May 2017                Cisplatin + pemetrexed      Tested       Palliative          20 May 2016            28 July 2017        After                             SD                  04 August 2016      Negative
                                                               T2a                N2     M1a                                     Pemetrexed mono            Tested                      Palliative   19 September 2016   03 November 2016       After               PD                                17 November2016                         
   3                                               EGFR        NSCLC - Adeno cc   T4     N2    M1    Thoracic aspiration         25 February 2016           Erlotinib mono              Tested       Palliative          26 January 2016        28 July 2016        Before                            PD                  13 July 2017        Negative
                                                               T4                 N2     M1                                      Osimertinib                \-                          Palliative   31 August 2016      30 June 2017           After               PD                                01 August 2017                          
                                                               T4                 N2     M1                                      Carboplatin + paclitaxel   Tested                      Palliative   09 August 2017      30 August 2017         After               PD                                18 September 2017                       
                                                               T4                 N3     M1c                                     Pemetrexed mono            Tested                      Palliative   11 October 2017     05 January 2018        After               PD                                25 January 2018                         
   4                                               WT          NSCLC - Adeno cc   T2a    N2    M1a   Thoracic aspiration         27 July 2016               Carboplatin + paclitaxel    Tested       Palliative          15 June 2016           26 August 2016      During                            PD                  08 September 2016   Negative
                                                               T4                 N3     M1b                                     Erlotinib mono             Tested                      Palliative   04 October 2016     12 December 2016       After               PD                                12 December 2016                        

The information ranges from the actual method of obtaining the sample, mutation analysis, diagnosis, staging (TNM=tumour, node, metastasis status) of the disease and applied treatment or treatments and clinical responses.

EGFR, epidermal growth factor receptor; KRAS, Kirsten rat sarcoma 2 viral oncogene homolog; NSCLC, non-small cell lung cancer; PD, progressive disease; PD-L1, programmed death ligand-1; RECIST, Response Evaluation Criteria In Solid Tumours; SD, stable disease.

Cells from cancer tissue or pleural effusion (PE) samples obtained from each patient were limited; therefore, the in vitro chemosensitivity tests were performed based on the clinical decision for treatment. The cryopreserved samples were thawed (viability routinely exceeded 90%; [online supplementary S. figure 1](#SP1){ref-type="supplementary-material"}), aggregates were made, then drug sensitivity tests were performed with drugs or drug combinations selected by the oncoteam ([online supplementary S. figure 2](#SP1){ref-type="supplementary-material"}). The in vitro viability test results were compared with the RECIST1.1 data.[@R16] In vitro mean viability values at and below 0.8 (induction of cell death 0.2\<) corresponded to patients with clinically SD, while a mean viability value of 0.9 and above (no or low level (\<0.1) induction of cell death) corresponded to patients with clinically PD ([figure 3A](#F3){ref-type="fig"}; [online supplementary table 1](#SP1){ref-type="supplementary-material"}). Cut-off values are explained in [online supplementary S. figure 3](#SP1){ref-type="supplementary-material"}. Sample numbers on the figure correspond to the patient numbers in [table 1](#T1){ref-type="table"}. The patient who donated the KRAS mutant solid tumour sample (S1) was PD during clinical observation, then following cisplatin+pemetrexed combination therapy became stable (SD). S1 patient became PD again after changing the treatment to pemetrexed monotherapy and the RECIST result correlated with the in vitro chemosensitivity analysis. The change in therapy was forced by severe adverse reactions to cisplatin. Patients S2 (wild type (WT)) and S9 (KRAS) responded well to cisplatin+vinorelbine combination as they were both SD at clinical examination and in vitro testing. Patients S4 (KRAS), S7 (KRAS), S8 (undisclosed mutation status) and S10 (EGFR) were SD correlating to the in vitro analysis. Patient samples S3 (KRAS), S5 (KRAS) and S6 (KRAS) remained firmly non-responsive to therapy and clinically PD after evaluation ([figure 3A](#F3){ref-type="fig"}). The in vitro test results correlated well with the clinical data ([figure 3A](#F3){ref-type="fig"}). Among the PE samples, donor of PE sample 2 (PE2) was initially SD after cisplatin+pemetrexed combination treatment but became PD when due to severe reactions to cisplatin, treatment was changed to pementrexed monotherapy ([figure 3A](#F3){ref-type="fig"}). The same chemosensitivity response was detected also in vitro. Discrepancies between clinical and in vitro evaluation were detected in some cases. Correcting the corresponding in vitro data with the time course of progression information ([figure 3B](#F3){ref-type="fig"}), a stronger association between the in vitro viability analysis and patient response to therapy ([figure 3C](#F3){ref-type="fig"}) was detected.
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![Chemosensitivity analysis. (A) Three-dimensional (3D) aggregate cultures were treated with patient-specific chemotherapeutic agents as determined by the oncoteam. After incubation at 37°C for 48 hours in a 96-well plate, ATP levels corresponding to cell viability were determined using a 3D CellTiter Glo kit. In vitro viability data were compared with Response Evaluation Criteria In Solid Tumours (RECIST1.1) data when it became available. Patient-specific data are shown individually and marked with the patient identifying number used in the study. (B) Individual patient data shown in association of time laps to disease progression. (C) Percentage of correspondence between clinical RECIST1.1 information and in vitro analysis results. PD, progressive disease; SD, stable disease.](bmjresp-2019-000505f03){#F3}

To investigate the possibility whether the above-mentioned in vitro drug sensitivity test could supplement the clinical decision-making process, a PE sample was selected for further studies. The patient who donated the sample did not respond to the clinically offered CBP--paclitaxel combination therapy (PD; [figure 4](#F4){ref-type="fig"}). The in vitro chemosensitivity analysis using CBP--paclitaxel matched the clinical response (relative cell viability values were above 0.9, no induction of cell death; [figure 4](#F4){ref-type="fig"}). Another, clinically approved combination for therapy in this particular case could have been CBP--pemetrexed. In vitro analysis of the sample using CBP--pemetrexed treatment of cell aggregates reduced cell viability below 0.8 (effective induction of cell death) that is in the SD range of the therapy response ([figure 4](#F4){ref-type="fig"}).

![Testing optional drug sensitivity. Clinical application of carboplatin--paclitaxel combination therapy resulted in progressive disease with a matching in vitro chemosensitivity analysis of cell viability values above 0.9. Treatment of tissue culture with carboplatin--pemetrexed in vitro reduced cell viability below 0.8 that is in the stable disease range of therapy response. Viability compared with the untreated control was significantly lower when cell cultures were incubated with carboplatin--pemetrexed combination (p\<0.01). PE, pleural effusion; N.S., not significant.](bmjresp-2019-000505f04){#F4}

Discussion {#s4}
==========

According to the US Precision Medicine Initiative,[@R21] the arsenal of precision medicine should be at the fingertips of every oncologist. The clinical reality, however, is different. Traditional chemotherapies are still the remaining treatment options for patients with stage III B or IV NSCLC tumours, that carry no targetable mutations, and are not positive for PD-L1. However, decision-making as chemosensitivity of the tumour is currently not tested routinely. Oncologists, who are bound by specific clinical guidelines, still need more than one treatment option to offer a patient. Even if the approved guidelines provide some choices, the fast progressing disease allows little time to select additional tests for the presence or absence of biomarkers indicating previously unpredicted therapeutic targets. The in vitro drug sensitivity analysis in the above study was performed to test whether the clinical effect of chemotherapeutic drug combinations could be tested using a simple and fast method where targeted therapy was not available for the patients. Compared with previous studies and test methods,[@R22] we intentionally remained within the current routine clinical boundaries. Instead of using a vast number of mutation analyses[@R23] and artificial intelligence[@R24] to achieve better accuracy, we simply selected the patient population more carefully. For example, patients who were subjected to Avastin or immune checkpoint treatment were excluded from the test, as the test tissue was lacking blood supply and contained no immune cells. Such strict selection criteria had the consequence of a drastically reduced number of patients whose in vitro and clinical data were suitable for comparison. Although the number of patients were limited in the study, the in vitro data indicate that in vitro chemosensitivity tests could aid clinical drug selection and potentially expand survival even for patients with advanced lung AC. The fact that we are able to test more than one chemotherapy combination in vitro ([figure 4](#F4){ref-type="fig"}) raises the possibility that an approved in vitro drug sensitivity test could make clinical decision-making easier. The in vitro process is feasible and could be easily added to the decision-making process. Partly, because it does not require additional sample taking from the patient and does not increase the workload of clinical staff.

In conclusion, chemosensitivity tests could supplement the clinical diagnostic arsenal as: (1) the assays can be performed from a small number of cells (1000 cell/well); therefore, even samples from distinct metastatic sites can be tested if sample taking is clinically feasible. (2) Cryopreservation of tumour cells allows sufficient time to perform additional diagnostic tests. (3) The analysis provides information within 48 hours, which is vital for patients with fast progressing tumours.

Additionally, the above system could also be introduced into drug development. To reduce systemic toxicity, novel prodrug systems are being developed.[@R25] Although the 3D tissue aggregate is not suitable to test most prodrugs, the toxic effects of the active metabolite can be tested in the above system.

The prediction of the clinical response to chemotherapeutic drugs remains a major challenge in clinical oncology. If our simple and fast in vitro method were to be used to test chemosensitivity and if that test result is added to the patient's full clinical assessment, a decision for therapy could be made with increased confidence.
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